Immune cell therapy, the fourth major cancer treatment following surgery, radiotherapy, and chemotherapy, has been recognized as the most active and promising treatment in the comprehensive tumor treatment in the 21st century.Read More…
CAR-T, Chimeric AntigenReceptor T-Cell Immunotherapy, is the most effective treatment of malignant tumors. Similar to other immunotherapy, its basic principle is to remove cancer cells in the use of the patient’s ownRead More…
CAR-T (Chimeric Antigen Receptor T-Cell), as an immunocytotherapy regimen, has attracted a lot of attention from academics, doctors, patients, and investors worldwide. What does make it so attractive and popular? CAR-T modifiesRead More…
Novartis’ chimeric antigen receptor T cell therapy (CAR-T) was supported and approved unanimously (10-0) on July 12th by the U.S. FDA Advisory Committee experts. This vote marks the key milepost of thisRead More…
On July 12, FDA experts will discuss whether CAR-T CTL019 can be on the market, which is an assessment of the CTL019 Biologics License Application (BLA) submitted by Novartis and will evaluateRead More…
On March 29, 2017, Novartis announced that the US FDA has issued a priority review for its CAR-T therapy CTL019 (tisagenlecleucel-T) biologics licensing application. The indications of CTL019 was recurrent or refractoryRead More…